Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment

Psychiatric Services : a Journal of the American Psychiatric Association
Bennett S LevitanJohn F P Bridges

Abstract

The objective of this study was to quantify patients' preferences related to benefits and risks of antipsychotic treatments for schizophrenia and to assess the relative importance of treatment attributes and adherence. Treatment-related preferences among U.S. residents with a self-reported physician diagnosis of schizophrenia were assessed via a discrete-choice experiment. Patients chose between competing hypothetical scenarios characterized by improvements in positive symptoms, negative symptoms, and social functioning; incidence of weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia; and medication formulation. Preferences were estimated by using a random-parameters logit model, and the impact of adherence was estimated with conditional logit models. The final sample consisted of 271 patients. Complete improvement in positive symptoms was the most preferred outcome (relative importance score of 10.0), followed by elimination of hyperglycemia (3.6, 95% confidence interval [CI]=2.6-4.6), improvement in negative symptoms (3.0, CI=1.6-4.3), reduced weight gain (2.6, CI=1.2-4.0), avoidance of hyperprolactinemia (1.7, CI=.9-2.6), improved social functioning (1.5, CI=.4-2.5), and avoidance of EPS (1.0, ...Continue Reading

Citations

Apr 14, 2016·British Journal of Clinical Pharmacology·Emily A F HolmesDyfrig A Hughes
Oct 12, 2017·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Victoria Alguera-LaraDavid Castle
Apr 27, 2018·Journal of Comparative Effectiveness Research·Daisy Ng-MakAntony Loebel
Nov 6, 2018·PharmacoEconomics·Vikas SoekhaiCaroline M Vass
Sep 26, 2017·Current Medical Research and Opinion·Kathleen BeusterienJohn F P Bridges
Aug 25, 2017·Early Intervention in Psychiatry·Mackenzie BeckerRobert B Zipursky
Jun 27, 2019·Journal of Mental Health·Vivien YeoDavid J Castle
Sep 7, 2019·Therapeutic Advances in Drug Safety·Juhaeri Juhaeri
Jan 13, 2021·Psychiatric Services : a Journal of the American Psychiatric Association·Nichole GoodsmithAlexander S Young
Nov 6, 2020·Patient Preference and Adherence·Michael J DoaneDawn I Velligan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.